Posts Archive

(GEM21menos65) (Isatuximab-VRD + ASCT) - (VRD extended + ASCT plus ERI) - (Isatuximab-VID + ASCT). ERI=Early Rescue Intervention...

(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...

CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480...

(SUCCESSOR-2) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib...

IFM 2020-02 MInimal Residual Disease Adapted Strategy (MIDAS) Isa-KRd NCT04934475: Phase 3 - IFM 2020-02 -MInimal Residual Disease...

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this...

bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of...

NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Iberdomide Combined With Low-dose...

NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma...

MCARH109 CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the...

IsKPd - IFM2018-03 NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in...

EMN26 NCT04564703: Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients Iberdomide (Cc220) Maintenance After...

CC-98633 CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With...

KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...